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Edited by Robert BaroukiAbstract Inducible cyclooxygenase-2 (COX-2) has been sug-
gested to play a role in the processes of inﬂammation and
carcinogenesis. Recent studies have shown the chemoprotective
eﬀects of kahweol and cafestol, which are coﬀee-speciﬁc
diterpenes. This study investigated the eﬀects of kahweol and
cafestol on the expression of COX-2 in lipopolysaccharide
(LPS)-activated RAW 264.7 macrophages. Kahweol and cafe-
stol signiﬁcantly suppressed the LPS-induced production of
prostaglandin E2, COX-2 protein and mRNA expression, and
COX-2 promoter activity in a dose-dependent manner. Further-
more, kahweol blocked the LPS-induced activation of NF-jB by
preventing IjB degradation and inhibiting IjB kinase activity.
These results will provide new insights into the anti-inﬂammatory
and anti-carcinogenic properties of kahweol and cafestol.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Macrophage1. Introduction
Cyclooxygenase (COX) catalyzes the synthesis of prosta-
glandins (PGs) from arachidonic acid. Two isozymes, COX-1
and COX-2, have been identiﬁed but are encoded by separate
genes. The COX-1 isozyme is believed to be a housekeeping
protein in most tissues and appears to catalyze the synthesis of
PGs for normal physiological functions. In contrast, COX-2 is
not present under normal physiological conditions but is
rapidly induced in various cell types by tumor promoters,
growth factors, cytokines and mitogens [1,2]. Many cell types
associated with inﬂammation, such as macrophages, endo-
thelial cells and ﬁbroblasts, express the COX-2 gene upon in-
duction [1]. It is well established that COX-2 is important in
carcinogenesis, and is over-expressed in transformed cells as
well as in various forms of cancer [1,2]. Because the targeted
inhibition of COX-2 is a promising approach to inhibiting
inﬂammation and carcinogenesis as well as to prevent cancer,
various chemopreventive strategies have focused on inhibitors
of the COX-2 enzyme activity. An equally important strategy
may be to identify the compounds that suppress the signaling
pathways that regulate COX-2 expression [3,4].* Corresponding author. Fax: +82-62-230-6639.
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doi:10.1016/j.febslet.2004.05.070COX-2 is an early gene expressed in response to many cy-
tokines. Its transcriptional regulation is, at least in part, under
the control of the transcription factor nuclear factor-jB (NF-
jB) [5]. In macrophages, LPS activates NF-jB, eventually
induces the expression of many immediate early genes [5]. The
presence of a cis-acting NF-jB element has been demonstrated
in the 50-ﬂanking regions of the COX-2 gene [5,6]. NF-jB
activation is induced by a cascade of events leading to the
activation of the inhibitor jB (IjB) kinase (IKK), which
phosphorylates IjB, leading to its degradation and ﬁnally re-
sulting in the translocation of NF-jB to the nucleus [6,7].
Because NF-jB plays a key role in regulating the genes in-
volved in the initiation of the immune, acute phase, and in-
ﬂammatory responses, there is growing interest in modulating
its activity. Therefore, the pathways leading to NF-jB acti-
vation are frequent targets for a variety of anti-inﬂammatory
drugs [6].
It is increasingly being acknowledged that foods and bev-
erages contain non-nutritional constituents that may have
beneﬁcial health eﬀects, such as anti-inﬂammatory and anti-
carcinogenic properties [8]. Kahweol and its dehydro deriva-
tive, cafestol (Fig. 1), are two diterpenes that are present in
considerable quantities in coﬀee beans, as well as in the ﬁnal,
unﬁltered beverage, e.g., in Turkish or Scandinavian style
coﬀees [9]. They have been shown to possess both adverse and
chemoprotective properties [10,11]. It is well known that both
kahweol and cafestol increase the blood cholesterol level in
both human and animal models [10]. However, animal studies
have shown that kahweol and cafestol oﬀer some protection
against the action of well-known carcinogens [12,13]. In line
with these observations, there is epidemiological evidence in
humans that the consumption of coﬀee with a high amount of
kahweol and cafestol is associated with a lower rate of colon
cancer [14]. The chemoprotective eﬀects of kahweol and cafe-
stol have thus far been primarily related to the beneﬁcial
modiﬁcations of the xenobiotic metabolism. Such eﬀects in-
clude the reduced activation of mutagens/carcinogens, e.g., via
the inhibition of the cytochrome P450 enzymes [12], as well as
their enhanced detoxiﬁcation, e.g., via the induction of car-
cinogen-detoxifying enzyme systems such as glutathione S-
transferase and UDP-glucuronosyl transferase [11,15].
Excessive prostaglandin E2 (PGE2) production by COX-2 in
stimulated inﬂammatory cells is believed to be a causative
factor associated with cellular injury in inﬂammatory disease.
Therefore, compounds inhibiting COX-2 activity or its tran-
scriptional activity might have anti-inﬂammatory or cancer
chemopreventive applications. This study investigated theblished by Elsevier B.V. All rights reserved.
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Fig. 1. Chemical structures of kahweol and cafestol. The arrows indicate the chemical diﬀerences between the two compounds; a double bond in
kahweol is lacking in cafestol.
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in murine macrophages. Herein, we show for the ﬁrst time that
kahweol and cafestol suppress the activation of COX-2 gene
expression via NF-jB inhibition by targeting the IKK
complex.2. Materials and methods
2.1. Chemicals and materials
The chemicals and cell culture materials used in this study were
obtained from the following sources: kahweol acetate, cafestol acetate,
and Escherichia coli 0111:B4 lipopolysaccharide (LPS) from Sigma
Co.; MTT-based colorimetric assay kit from Roche Co.; prostaglandin
E2 (PGE2) and enzyme immunoassay reagents for the PGE2 assays
from Cayman Co.; LipofectAMINE Plus, RPMI 1640 medium, fetal
bovine serum (FBS), and penicillin-streptomycin solution from Life
Technologies, Inc.; pGL3-4jB-Luc and the luciferase assay system
from Promega; pCMV-b-gal from Clonetech; GST-IjBa and anti-
bodies to COX-2, COX-1, b-actin, IKKb, IjBa, and the phosphory-
lated form of IjBa (Ser 32) from Santa Cruz Biotechnology, Inc.;
Western blotting detection reagents (ECL) from Amersham Pharmacia
Biotech.; the other chemicals were of the highest commercial grade
available.
2.2. Cell culture and cell viability assay
The mouse macrophage cell line, RAW 264.7 cells, was obtained
from the American Type Culture Collection (Bethesda, MD), and
grown in RPMI 1640 supplemented with 10% fetal bovine serum, 2
mM L-glutamine, 100 U/ml penicillin, and 100 lg/ml streptomycin at
37 C in a 5% CO2 humidiﬁed incubator. Kahweol acetate and cafestol
acetate were dissolved in dimethyl sulfoxide and added directly to the
culture media. The control cells were treated with the solvents only, the
ﬁnal concentration of which never exceeded 0.1%, which is a concen-
tration that did not have any noticeable eﬀect on the assay systems.
The cell viability was assessed using a MTT assay according to the
manufacturer’s instructions.
2.3. Determination of PGE2 production
The cells were incubated with the chemicals and/or LPS (0.5 lg/ml).
After incubating the cells for 24 h, the culture medium was collected
and the level of PGE2 released into culture media was measured using
a speciﬁc enzyme immunoassay according to the manufacturer’s
instructions.
2.4. Immunoblot analysis
The cells were cultured with the chemicals and/or LPS (0.5 lg/ml) for
24 h and equal amounts of the total cellular protein (50 lg) were re-
solved by 10% SDS–PAGE and transferred onto polyvinylidene di-
ﬂuoride membranes. After blocking, the membranes were incubated
with COX-2 polyclonal antiserum, COX-1 polyclonal antiserum or
monoclonal anti-b-actin. The secondary antibody to IgG conjugated
to horseradish peroxidase was used. The blots were probed with the
ECL Western blot detection system according to the manufacturer’s
instructions.2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis
The cells were cultured with the chemicals and/or LPS (0.5 lg/ml) for
3 h. The total cellular RNA was isolated using an acidic phenol ex-
traction procedure. cDNA synthesis, semiquantitative RT-PCR for
COX-1, COX-2, and b-actin mRNA, and the analysis of the results
were all performed as previously described [16].
2.6. Transient transfection and luciferase and b-galactosidase assays
The cells were transiently co-transfected with the plasmids (the
COX-2 promoter construct ()327/+59) and its NF-jB mutant con-
structs (designated KBM, )223/)214) have been described previously
[17], which were generous gifts from Dr. Tadashi Tanabe and Chieko
Yokoyama (National Cardiovascular Center Research Institute, Osa-
ka, Japan), pGL3-4jB-Luc, and pCMV-b-gal) using LipofectAMINE
Plus according to the manufacturer’s protocol. After 18 h, the cells
were treated with the chemicals and/or LPS (0.5 lg/ml) for 12 h, which
were then lysed. The luciferase and b-galactosidase activity were de-
termined as described previously [18]. The luciferase activity was
normalized with respect to the b-galactosidase activity and was ex-
pressed relative to the activity of the LPS group.
2.7. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as previously described [18]. Two
double-stranded deoxyoligonucleotides containing the NF-jB binding
site (50-CAGAGGGGACTTTCCGAGAG-30, bold and underlined
indicates NF-jB core consensus sequences) were end-labeled with [c-
32P]dATP. Nuclear extracts (5 lg) were incubated with 2 lg of
poly(dI–dC) and the 32P-labeled DNA probe in binding buﬀer (100
mM NaCl, 30 mM HEPES, 1.5 mM MgCl2, 0.3 mM EDTA, 10%
glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl ﬂuoride, 1
lg/ml concentration each of aprotinin and leupeptin) for 10 min on ice.
DNA was separated from the free probe using a 4.8% polyacrylamide
gel in 0.5 TBE buﬀer (44.5 mM Tris, 44.5 mM boric acid, and 1 mM
EDTA). Following electrophoresis, the gel was dried and subjected to
autoradiography.
2.8. IjBa degradation and IKK assay
The cytoplasmic extracts were prepared from the cells treated with
the chemicals and LPS (0.5 lg/ml) for 30 min. The extracts were then
resolved on 10% SDS–PAGE and analyzed by immunoblotting using
an antibody against IjBa, as described above. For the IKK assay,
the cells were treated with the chemicals for 30 min, and equal
amounts of the total cellular protein (800 lg) were immunoprecipi-
tated with the IKKb antibody and protein A/G-PLUS agarose for 12
h at 4 C. The kinase assay was carried out in a kinase buﬀer con-
taining 5 lM cold ATP, 10 lCi [c-32P]ATP (5000 Ci/mmol) and 1 lg
of the GST-IjBa fusion protein as a substrate, and incubated for 20
min at 25 C. The reaction was quenched by adding the Laemmli
buﬀer followed by boiling for 5 min. The samples were subjected
to 10% SDS–PAGE, transferred to polyvinylidene diﬂuoride
membranes, analyzed by autoradiography, and ﬁnally subjected to
immunoblotting.
2.9. Statistical analysis
All experiments were repeated at least three times. MeansS.D.
were calculated for each group and Dunnet’s ‘t’ test was used to cal-
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signiﬁcant.3. Results
3.1. Eﬀects of kahweol and cafestol on PGE2 production in
LPS-activated macrophages
In order to investigate their anti-inﬂammatory eﬀects, kah-
weol and cafestol (Fig. 1) were tested with regard to their eﬀect
on PGE2 production in the LPS-activated RAW 264.7 mac-
rophages. When the cells were treated with the various con-
centrations of kahweol and cafestol, the PGE2 production
induced by LPS was signiﬁcantly inhibited in a dose-dependent
manner (Fig. 2), and the kahweol was much more eﬀective in
inhibiting PGE2 production than cafestol. The cell viability
was assessed by a MTT assay. An examination of the cyto-
toxicity of kahweol and cafestol in the RAW 264.7 macro-
phages indicated that these compounds did not adversely aﬀect
the cell viability (>90% cell viability, Fig. 2). Therefore, the
inhibition of LPS-induced PGE2 production by kahweol and
cafestol was not the result of their cytotoxicity against the cells.
3.2. Eﬀects of kahweol and cafestol on the COX-2 expression in
LPS-activated macrophages
Western blotting of the cell lysate protein was carried out in
order to determine if the above eﬀects on PGE2 production
were related to diﬀerences in the COX levels. LPS induced
COX-2 in the macrophages, and a treatment with kahweol and
cafestol caused a dose-dependent decrease in the LPS-medi-
ated induction of COX-2 (Fig. 3A). Kahweol is much more
eﬀective at inhibiting COX-2 expression than cafestol. Neither
LPS nor kahweol and cafestol aﬀected the COX-1 level (data
not shown).
The observed changes in the COX-2 protein level might be a
reﬂection of a change in protein synthesis or degradation. The
COX-2 mRNA levels were measured by RT-PCR analysis inFig. 2. The eﬀects of kahweol and cafestol on PGE2 production. The
cells were treated with kahweol or cafestol in the presence of LPS (0.5
lg/ml). The supernatants were harvested 24 h later and assayed for
PGE2 production. The cell viability was evaluated with the MTT assay
(solid line connecting solid circles). The results are presented as a
percentage of the control value obtained from non-treated cells. The
values are expressed as means S.D. of three individual experiments,
performed in triplicate. *P < 0:01 compared with the LPS alone.order to further elucidate the mechanism responsible for the
changes in the amount of the COX-2 protein. Kahweol and
cafestol markedly decreased the COX-2 mRNA levels induced
by LPS (Fig. 3B). This suggests that kahweol and cafestol
suppress COX-2 expression at the transcriptional level, thereby
contributing to decreasing the production of the COX-2 pro-
tein and PGE2.
3.3. Eﬀects of kahweol on the activation of NF-jB in
LPS-activated macrophages
NF-jB activation is essential for the induction of COX-2 by
LPS or other inﬂammatory cytokines [5] and kahweol is much
more eﬀective at inhibiting PGE2 production and COX-2 ex-
pression by LPS than cafestol. Therefore, this study investi-
gated whether or not kahweol could suppress NF-jB
activation in the LPS-activated macrophages using an elec-
trophoretic mobility shift assay. The induction of the NF-jB
binding activity by LPS was markedly inhibited by kahweol in
a dose-dependent manner (Fig. 4A, upper panel). The addition
of an excessive quantity of an unlabeled wild type probe
completely prevented the NF-jB binding (Fig. 4A, upper pa-
nel), demonstrating the binding speciﬁcity of the NF-jB
complex. The addition of anti-p65 or anti-p50 antibody to the
reaction mixture obtained from the LPS-treated cells caused a
supershift in NF-jB binding, whereas the anti-RelB antibody
did not shift the retarded band (Fig. 4A, lower panel). Su-
pershift assays using antisera against p50, p65, or RelB indi-
cated that this protein complex contained the p50 and p65
subunits of NF-jB.
In order to further investigate the importance of LPS and
kahweol in modulating the expression of COX-2 and NF-jBFig. 3. The eﬀect of kahweol and cafestol on LPS-induced expression
of the COX-2 protein and mRNA. The cells were treated with either
kahweol or cafestol in the presence of LPS (0.5 lg/ml). (A) Immuno-
blot analysis. After 24 h of incubation, the cell lysates (30 lg protein)
were separated by SDS–PAGE, transferred to a nitrocellulose mem-
brane and blotted with an anti-COX-2 or b-actin antibody. (B) RT-
PCR analysis. After 3 h of incubation, the total RNA was prepared
and RT-PCR was performed as described in Section 2. The PCR
products were separated on a 1.2% agarose gel and stained with
ethidium bromide. These blots (A and B) are representatives of each of
three independent experiments.
Fig. 4. Eﬀects of kahweol on (A) LPS-induced NF-jB activity determined by EMSA, (B) pNF-B-Luc and COX-2 promoter-Luc reporter plasmids,
(C) IjB degradation and (D) LPS-induced IjB kinase activity. (A) The cells were treated with kahweol and LPS (0.5 lg/ml) for 30 min. The nuclear
extracts were prepared and EMSA was carried out (upper panel). The speciﬁcity of NF-jB binding was conﬁrmed by supershift analysis using the
antibodies directed against p65, p50, or RelB protein (lower panel). The arrow indicates the NF-jB binding complex and SS indicates supershift of
the retarded NF-jB band. Excess NF-jB; 200-fold molar excess of non-labeled NF-jB probe. (B) The cells were transiently co-transfected with
pGL3-4jB-Luc, COX-2 promoter-Luc, or NF-jB mutant COX-2 promoter-Luc (mNF-jB, KBM) and pCMV-b-gal. After 18 h, the cells were
treated with kahweol in the presence of LPS (0.5 lg/ml) or TNFa (5 ng/ml) for 12 h, harvested and their luciferase and b-galactosidase activities were
determined. The luciferase activities were expressed relative to the LPS. The values are expressed as meansS.D. of three individual experiments,
performed in triplicate. *P < 0:01 compared with the LPS or TNFa alone. (C) The cells were treated with kahweol and LPS (0.5 lg/ml) for 30 min.
Total cellular protein (50 lg) was separated on 10% SDS–PAGE and blotted with antibody speciﬁc for IjB. (D) The cells were treated with kahweol
and LPS (0.5 lg/ml) for 30 min and IKK was immunoprecipitated from cell lysates using IKKb Ab. The activity of immunoprecipitated IKK was
measured using GST-IjBa as substrate and GST-p-IjBa was visualized by autoradiography. Relative amount of IKKb in the precipitated complex
was determined by immunoblot (upper panel). IKK was immunoprecipitated from LPS-activated cells and IKK activity was measured in the absence
or presence of kahweol added to the assay mixture. IKK activity was assessed using GST-IjBa as described for upper panel (lower panel). These
blots (A, C, and D) are representatives of each of three independent experiments.
324 J.Y. Kim et al. / FEBS Letters 569 (2004) 321–326
J.Y. Kim et al. / FEBS Letters 569 (2004) 321–326 325activity in the LPS-activated macrophages, transient transfec-
tions were performed using the COX-2 luciferase promoter
construct and the NF-jB-dependent luciferase reporter plas-
mid. Kahweol inhibited the LPS- or TNFa-activated COX-2
promoter activity and NF-jB transcriptional activity
(Fig. 4B). These results suggest that the suppression of COX-2
expression by kahweol occurred via the inhibition of NF-jB
activation. In addition, to evaluate the role of the NF-jB site
in the expression of COX-2 gene and to determine the eﬀects of
kahweol on the NF-jB activation by LPS, the cells were
transfected with the luciferase reporter vector KBM which is
driven by the COX-2 promoter region ()327/+59) speciﬁcally
mutated at its NF-jB site ()223/)214) [17]. When the cells
were transfected with KBM, although LPS-inducible promoter
activity was decreased, kahweol further inhibited LPS-acti-
vated promoter activity (Fig. 4B). These results suggest that
the other cis-acting element(s) may also be responsible for the
eﬀects of kahweol on COX-2 expression. The experiments to
assess whether kahweol changes the activities of other tran-
scriptions factors (i.e., NF-IL-6, CRE) required for the COX-2
gene expression remain to be carried out. In contrast, mutation
of the NF-jB site abolished the enhanced promoter activity by
TNFa (Fig. 4B). NF-jB site at )223/)214 is critical for TNFa-
induced COX-2 expression consistent with reported results
[19]. Taken together, these results suggest that the NFjB is
involved in the LPS-induced COX-2 expression and the sup-
pression of COX-2 expression by kahweol occurred via the
inhibition of NF-jB activation.
Since it has been well documented that NF-jB activation
correlates with the rapid proteolytic degradation of IjB, the
prevention of IjB degradation was also examined as an indi-
cation that kahweol inhibits NF-jB activation. LPS induced a
transient degradation of IjBa in the cells, whereas kahweol
prevented the degradation of IjB (Fig. 4C). Since IjB is
phosphorylated by the IKK, the eﬀect of kahweol on the cel-
lular IKK activation was determined (Fig. 4D). The cells were
activated by LPS in the presence of kahweol. The IKK com-
plex was immunoprecipitated from cell lysates and analyzed
for IKK activity using GST-IjBa as substrate. The blot used
for the autoradiogram was subsequently probed for IKKb by
immunoblot analysis. Kahweol signiﬁcantly inhibited the IKK
activity induced by LPS (Fig. 4D). However, kahweol had
little or no eﬀect on the IKK protein level (Fig. 4D, upper
panel), suggesting that the inhibition of LPS-induced IKK
activity by kahweol was not due to the decreased IKK ex-
pression level. Additional experiments were carried out to
more stringently test the eﬀect of kahweol on IKK activity.
IKKb was immunoprecipitated from the cell lysates of the
LPS-activated cells and kahweol was added at the beginning of
the assay for IKK activity. The activity of IKK was not af-
fected by the presence of kahweol (Fig. 4D, lower panel).
These results suggest that the inhibition of COX-2 expression
by kahweol occurred via the suppression of IKK activity,
which resulted in the prevention of NF-jB activation.4. Discussion
Recent studies have shown that kahweol and cafestol have
anti-carcinogenic eﬀects. The results in this study link the ef-
fects of kahweol and cafestol to the inhibition of PGE2 pro-duction. With regard to PGE2 production, it was shown that
kahweol and cafestol inhibit the LPS-activated induction of
COX-2 in the macrophages.
The chemopreventive or anti-carcinogenic properties of
kahweol and cafestol can be understood, at least in part, from
the induction of several beneﬁcial modiﬁcations to the xeno-
biotic metabolism, which, depending on the individual com-
pound, may involve both the reduced activation and enhanced
detoxiﬁcation of mutagens/carcinogens [11–13,15]. Epidemio-
logical studies have revealed a protective association between
coﬀee consumption and the risk of certain types of cancer in-
cluding colon cancer [14,20,21]. Meanwhile, COX-2 has been
implicated in the carcinogenic processes [2], and its over-ex-
pression by malignant cells has been shown to enhance cellular
invasion, induce angiogenesis, regulate the anti-apoptotic cel-
lular defenses and augment the immunological resistance via
PGE2 production [22]. In addition, it has been demonstrated
that COX-2 is over-expressed in colon cancer patients [23].
There is growing evidence to suggest that inhibitors of COX-
2 activity can be eﬀective anti-inﬂammatory agents, as well as
being beneﬁcial in the prevention and treatment of colon
cancer [3,24]. Therefore, agents that interfere with the signaling
mechanisms governing the transcription of COX-2 should also
inhibit inﬂammation and tumorigenesis [3,4]. The major focus
of this study was to investigate the eﬀects of kahweol and
cafestol on COX-2 expression using a macrophage model. This
study showed that kahweol and cafestol, which are both coﬀee
diterpenes, inhibit PGE2 production in LPS-stimulated mac-
rophages in a dose-dependent manner. Moreover, kahweol
had a larger eﬀect on PGE2 production than cafestol (Fig. 2).
This suggests the possible suppression of COX-2 induction by
these compounds. Therefore, the eﬀect of kahweol and cafestol
on COX-2 expression was investigated in order to obtain a
better understanding of the inhibitory mechanism of PGE2
production. It was found that the simultaneous treatment of
either kahweol or cafestol with LPS signiﬁcantly inhibited
COX-2 mRNA and protein expression (Fig. 3). Kahweol had a
more potent inhibitory eﬀect on PGE2 production and the
COX-2 expression than cafestol. These phenomena might de-
pend on the structures of these two diterpenes (Fig. 1). The
absence of one double bond on the A ring of kahweol increases
its potency in suppressing COX-2 expression in a diﬀerent
manner to that of cafestol. The presence of this single double
bond within the A ring of cafestol appears to be less eﬀective in
inhibiting COX-2 expression than kahweol. Future experi-
ments will be needed to determine the relationship between the
structures of these two diterpenes and their diﬀerent eﬃcacy.
The administration of kahweol and cafestol (2–10 mg/kg, i.p.)
was also observed to block COX-2 expression in the cells
present in the exudate and produced a dose-dependent de-
crease in PGE2 production in an in vivo mouse air pouch
model of carrageenan-induced inﬂammation (data not shown).
Animal studies have demonstrated that kahweol and cafestol
have chemoprotective properties (anti-carcinogenic eﬀects)
against carcinogens [11–13]. Carcinogenesis typically involves a
cellular transformation, hyperproliferation, invasion, angio-
genesis, and metastasis. Various carcinogens, inﬂammatory
agents, and tumor promoters activate these processes. Carcin-
ogenic agents, such as nitrosamines, 7,12-dimethylbenz[a]an-
thracene, and aﬂatoxin B1 have been shown to activate NF-jB
[25,26]. These agents have been used to examine the anti-car-
cinogenic eﬀects of kahweol and cafestol in animal studies.
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of a number of genes whose products are involved in carcino-
genesis/tumorigenesis [27,28]. Because the suppression of NF-
jB has been implicated in chemoprevention, it is also possible
that the anti-carcinogenic eﬀects of kahweol are mediated via
the suppression of NF-jB-dependent gene expression.
This study demonstrated that kahweol and cafestol suppress
the LPS-activated expression of COX-2, which has NF-jB
binding sites in its promoter, and regulate its transcription in
macrophages. Furthermore, it was found that kahweol inhib-
ited the LPS-induced activation of IKK, IjBa phosphoryla-
tion and degradation. The phosphorylation of IjB is regulated
by IKK, which in turn is regulated by many upstream kinases,
including NIK, Akt, and mitogen-activated protein kinase
kinase kinase 1 [6,7,27]. This study found that kahweol did not
directly aﬀect the activity of IKK (Fig. 4D), which suggests
that kahweol inhibits the LPS-induced IKK activity by an
indirect mechanism. Therefore, it is possible that kahweol in-
hibits IKK activation by inhibiting one or more of the up-
stream kinases responsible for IKK activation.
Although the down-regulatory ability of kahweol on COX-2
expression was demonstrated by the inhibition of NF-jB ac-
tivation in the LPS-stimulated macrophages, the precise
mechanism by which kahweol suppresses COX-2 expression in
the macrophages and exerts its anti-inﬂammatory eﬀects is still
largely unknown. The activation of the MAPK members,
ERK and p38 MAPK, have been shown to be involved in the
stimulation of NF-jB activity and the subsequent expression
of COX-2 in the LPS-activated macrophages [29]. Kahweol
might also inhibit the activity of these kinases, leading to NF-
jB activation before or during the IjB phosphorylation step.
The suppression of NF-jB activation by kahweol may par-
tially account for this. This is because there are responsive
elements on the promoters of the COX-2 gene. However, other
cis-acting elements such as the CRE and the NF-IL6 site are
also involved in the transcriptional regulation of the COX-2
gene [17]. Therefore, further studies of the eﬀects of kahweol
on the other cis-acting elements are necessary to understand
the regulation of the COX-2 gene expression by kahweol and
clarify the mechanisms involved.
In conclusion, the coﬀee-speciﬁc diterpenes, kahweol and
cafestol, were found to inhibit PGE2 production and COX-2
expression in macrophages via the inhibition of NF-jB acti-
vation. These novel ﬁndings may help identify other mecha-
nisms for the anti-inﬂammatory or cancer chemopreventive
activities, and provide new insights into the previously unrec-
ognized biological activity of kahweol and cafestol.
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